Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Aldesleukin + KK-LC-1 TCR-T cells |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Aldesleukin | Proleukin | IL-2|Interleukin-2|IL2 | Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary). | |
| KK-LC-1 TCR-T cells | Autologous Anti-KK-LC-1 TCR-expressing T-cells | KK-LC-1 TCR-T cells are T-lymphocytes engineered to express a T-cell receptor (TCR) targeting KK-LC-1 (CT83), which may inhibit growth KK-LC-1 (CT83)-expressing tumors (PMID: 31455429). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05483491 | Phase I | Aldesleukin + KK-LC-1 TCR-T cells | KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | Recruiting | USA | 0 |